While running a research site, Barry Lake became frustrated with the manual methods of his clinical trial pipeline administration and inability to automate and track the efficiency of study startup workflows. Traditional “CTMS” focuses solely on “clinical” automation like patient visit scheduling and invoicing the trial sponsor for those visits. Such CTMS applications have very limited, trial-specific reporting capabilities and no ability to capture and display a research site’s performance metrics so management can validate their site’s efficiency in trial startup and screening and enrollment performance. In other words, traditional CTMS lacks the capability to capture and use performance metrics data to allow you to differentiate your site or network from any other research organization. Given this major gap in the technology stack, Lake founded Devana Solutions in 2016, creating the first-of-its-kind and, even today, the only study startup workflow automation, performance metrics capture and analysis platform for trial sites and networks. Devana was acquired by RealTime-eClinical Solutions in 2023, and today, rt-Devana’s “category-defining” SaaS products now count virtually every leading major clinical trial site network as a valued client-partner helping cross-functional teams at independent trial site networks, academic medical centers and health systems automate and efficiently manage trial startup workflows. Most importantly, rt-Devana seamlessly captures and calculates site performance metrics as all cross-functional users interact with the rt-Devana system from trial startup through execution. The system drives performance transparency and accountability across your entire research organization, empowering leadership to display and analyze critical performance-metrics. As a result, rt-Devana has become “mission critical” to the world’s leading site networks. In the second half of 2025, rt-Devana’s next-generation SaaS innovation will greatly advance rt-Devana’s quest to unite all clinical trial stakeholders through performance data transparency, from sponsors to CROs to sites. Better operational alignment through performance transparency between trial stakeholders will greatly reduce clinical trial cycle time and costs. As a result, rt-Devana will take a giant leap forward in completing its mission of speeding therapeutic advances to the stakeholders that truly matter the most: patients.